These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26632357)

  • 41. Reproductive CRISPR does not cure disease.
    Rulli T
    Bioethics; 2019 Nov; 33(9):1072-1082. PubMed ID: 31489967
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Harnessing CRISPR-Cas systems for bacterial genome editing.
    Selle K; Barrangou R
    Trends Microbiol; 2015 Apr; 23(4):225-32. PubMed ID: 25698413
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Human Right to Science and the Regulation of Human Germline Engineering.
    Boggio A; Knoppers BM; Almqvist J; Romano CPR
    CRISPR J; 2019 Jun; 2():134-142. PubMed ID: 31225756
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Realigning gene editing with clinical research ethics: What the "CRISPR Twins" debacle means for Chinese and international research ethics governance.
    Kleiderman E; Ogbogu U
    Account Res; 2019 May; 26(4):257-264. PubMed ID: 31068009
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Smart Programmable CRISPR Technology: A Next Generation Genome Editing Tool for Investigators.
    Chakraborty C; Teoh SL; Das S
    Curr Drug Targets; 2017; 18(14):1653-1663. PubMed ID: 27231109
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CRISPR/Cas9 in zebrafish: an efficient combination for human genetic diseases modeling.
    Liu J; Zhou Y; Qi X; Chen J; Chen W; Qiu G; Wu Z; Wu N
    Hum Genet; 2017 Jan; 136(1):1-12. PubMed ID: 27807677
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CRISPR-Cas in Medicinal Chemistry: Applications and Regulatory Concerns.
    Duardo-Sanchez A
    Curr Top Med Chem; 2017; 17(30):3308-3315. PubMed ID: 29231142
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The potential application and challenge of powerful CRISPR/Cas9 system in cardiovascular research.
    Li Y; Song YH; Liu B; Yu XY
    Int J Cardiol; 2017 Jan; 227():191-193. PubMed ID: 27847153
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CRISPR/Cas9-mediated correction of human genetic disease.
    Men K; Duan X; He Z; Yang Y; Yao S; Wei Y
    Sci China Life Sci; 2017 May; 60(5):447-457. PubMed ID: 28534256
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Shaping the CRISPR Gene-Editing Debate: Questions About Enhancement and Germline Modification.
    Johnston J
    Perspect Biol Med; 2020; 63(1):141-154. PubMed ID: 32063593
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CRISPR/Cas9: at the cutting edge of hepatology.
    Pankowicz FP; Jarrett KE; Lagor WR; Bissig KD
    Gut; 2017 Jul; 66(7):1329-1340. PubMed ID: 28487442
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genome modification by CRISPR/Cas9.
    Ma Y; Zhang L; Huang X
    FEBS J; 2014 Dec; 281(23):5186-93. PubMed ID: 25315507
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Germline genome-editing research and its socioethical implications.
    Ishii T
    Trends Mol Med; 2015 Aug; 21(8):473-81. PubMed ID: 26078206
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Designing Ethical Trials of Germline Gene Editing.
    Cwik B
    N Engl J Med; 2017 Nov; 377(20):1911-1913. PubMed ID: 29141166
    [No Abstract]   [Full Text] [Related]  

  • 55. Bioethics Panels Open Door Slightly to Germline Gene Editing.
    Lyon J
    JAMA; 2017 Nov; 318(17):1639-1640. PubMed ID: 29049747
    [No Abstract]   [Full Text] [Related]  

  • 56. CRISPR: gene editing is just the beginning.
    Ledford H
    Nature; 2016 Mar; 531(7593):156-9. PubMed ID: 26961639
    [No Abstract]   [Full Text] [Related]  

  • 57. CRISPR and the Rebirth of Synthetic Biology.
    Heidari R; Shaw DM; Elger BS
    Sci Eng Ethics; 2017 Apr; 23(2):351-363. PubMed ID: 27325413
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Extending CRISPR-Cas9 Technology from Genome Editing to Transcriptional Engineering in the Genus Clostridium.
    Bruder MR; Pyne ME; Moo-Young M; Chung DA; Chou CP
    Appl Environ Microbiol; 2016 Oct; 82(20):6109-6119. PubMed ID: 27496775
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multistage regulator based on tandem promoters and CRISPR/Cas.
    Jia H; Liang T; Wang Z; He Z; Liu Y; Yang L; Zeng Y; Liu S; Tang L; Wang J; Chen Y; Xie Z
    ACS Synth Biol; 2014 Dec; 3(12):1007-10. PubMed ID: 25524111
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Editing and investigating genomes with TALE and CRISPR/Cas systems: applications of artificial TALE and CRISPR-Cas systems.
    Giovannangeli C; Concordet JP
    Methods; 2014 Sep; 69(2):119-20. PubMed ID: 25248487
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.